Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have received an average recommendation of "Buy" from the five research firms that are covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $6.00.

CNTX has been the topic of several recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. D. Boral Capital reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Thursday, May 8th. William Blair reaffirmed an "outperform" rating on shares of Context Therapeutics in a research report on Tuesday, April 29th. Finally, Piper Sandler restated an "overweight" rating and set a $4.00 price objective (down previously from $4.50) on shares of Context Therapeutics in a research report on Thursday.

Context Therapeutics Stock Performance

Shares of CNTX stock traded down $0.01 during trading hours on Thursday, reaching $0.64. The company had a trading volume of 122,239 shares, compared to its average volume of 273,334. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $2.75. The stock has a fifty day moving average of $0.72 and a 200-day moving average of $0.85. The company has a market capitalization of $57.59 million, a price-to-earnings ratio of -2.07 and a beta of 1.86.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). On average, analysts forecast that Context Therapeutics will post -0.51 EPS for the current year.

Insider Buying and Selling

In related news, CEO Martin A. Lehr purchased 100,000 shares of Context Therapeutics stock in a transaction on Monday, June 9th. The stock was purchased at an average cost of $0.70 per share, with a total value of $70,000.00. Following the acquisition, the chief executive officer now directly owns 920,190 shares in the company, valued at approximately $644,133. This trade represents a 12.19% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Jennifer Lynn Minai-Azary acquired 40,010 shares of the company's stock in a transaction dated Friday, June 6th. The shares were bought at an average price of $0.64 per share, for a total transaction of $25,606.40. Following the acquisition, the chief financial officer now owns 80,010 shares in the company, valued at approximately $51,206.40. This trade represents a 100.03% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 160,010 shares of company stock worth $107,206. Corporate insiders own 2.80% of the company's stock.

Hedge Funds Weigh In On Context Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CNTX. Jane Street Group LLC bought a new stake in shares of Context Therapeutics during the fourth quarter valued at approximately $29,000. Citadel Advisors LLC bought a new position in shares of Context Therapeutics in the 4th quarter valued at about $31,000. Shay Capital LLC acquired a new stake in shares of Context Therapeutics during the fourth quarter worth $52,000. Landscape Capital Management L.L.C. bought a new position in Context Therapeutics during the 4th quarter worth approximately $94,000. Finally, Walleye Capital LLC boosted its stake in Context Therapeutics by 51.7% during the 4th quarter. Walleye Capital LLC now owns 166,306 shares of the company's stock worth $175,000 after acquiring an additional 56,651 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.